PTEN基因与甲状腺乳头状癌相关性研究进展

洪海燕; 石建华

留言板

尊敬的读者、作者、审稿人, 关于本刊的投稿、审稿、编辑和出版的任何问题, 您可以本页添加留言。我们将尽快给您答复。谢谢您的支持!

姓名
邮箱
手机号码
标题
留言内容
验证码

PTEN基因与甲状腺乳头状癌相关性研究进展

洪海燕 , 石建华

文章导航 > 蚌埠医学院学报 > 2013, 37 > 4: (502-505)

引用本文:

Citation:

PTEN基因与甲状腺乳头状癌相关性研究进展

1.
蚌埠医学院第一附属医院内分泌科, 233004

作者简介: 洪海燕(1986－ ),女,硕士研究生.

基金项目:

摘要: 恶性肿瘤的发生、发展涉及遗传因素和环境因素等多种病因,在其发生、发展过程中有多个癌基因和/或抑癌基因发生改变,常导致细胞生长失控,从而引起恶性肿瘤。
- 甲状腺肿瘤 /
- PTEN基因 /
- 综述

[2] Myers MP,Stolarov JP,Eng C, et al.PTEN, the tumor suppressor from human chromosome 10q23, is a dual-specificity phosphatase[J].Proc Natl Acad Sci USA,1997, 94( 17):9052-9057.
[2]	Li J,Yen C,Liaw D,et al.PTEN,a puptative protein tyrosine phosphatase gene mutated in human brain,breast mad prostate cancer[J].Science, 1997,275( 5308):1943-1947.
[3] Diallo-Krou E,Yu J,Colby LA, et al.Paired box gene 8-peroxisome proliferator-activated receptor-gamma fusion protein and loss of phosphatase and tensin homolog synergistically cause thyroid hyperplasia in transgenic mice[J].Endocrinology,2009,150( 11):5181-5190.
[4] Hobert JA,Eng C.PTEN hamartoma tumor syndrome:all overview[J].Genet Med,2009,11( 10):687-694.
[5] Simpson L,Parsons R.PTEN:life as a tumor suppressor[J].Exp Cell Res,200l,264( 1):29-41.
[6] Diaz-Meco MT,Baker S.The Par.4 /PTEN connection in tumorsuppression[J].Cell Cycle,2009,8( 16):2518-2522.
[7] Jiang BH,Liu LZ.P13K/PTEN signaling in angiogenesis and tumorigenesis[J].Adv Cancer Res,2009,102:19-65.
[8] Wan X,Yokoyama Y,Shinohara A,et al.PTEN augments staurosporine-induced apoptosis in PTEN-null Ishikawa cells by downregulating P13K/Akt signaling pathway [J].Cell Death Differ,2002,9( 4):414-420.
[9] Romashkova JA.Makarov SS.NF-B is a target of AKT in antiapototic PDGF signaling[J].Nature, 1999,401( 6748):86 -90.
[10] Rohn JL,Hueber AO,McCarthy NJ, et al.The opposing roles of the Akt and c-Myc signalling pathways in survival from CD95-mediated apoptosis[J].Oncogene, 1998,17( 22):2811-2818.[11 ] Sulis ML,Parsons R.PTEN:from pathology to biology[J].Trends Cell Biol,2003,3( 9):478-483.
[12] Yart A,Laffargue M,Mayeux P.A critical role for phosphoinositide3-kinase upstream of Gabl and SHP2 in the activation of ras and mitogen-activated protein kinases by epidermal growth factor[J].J Boils Chem,2001,276( 12):8856-8864.
[13] Di CA,Pandolfi PP.The multiple roles of PTEN in tumor suppression[J].Cell,2000,100( 4):387-390.
[14] Tamura M,Gu J,Matsumot oK, et al.Inhibition of cell migration,spreading, and focal adhesions by tumor suppressor PTEN[J].Science,1998,280( 5369):1614-1617.
[15] Jones G,Machado J,Merlo A.Loss of focal adhesion kinase inhibits epidermal growth factor receptor-dependent migration and induces aggregation of NH2-terminal FAK in the nuclei of apoptotic glioblastoma cells[J].Cancer Res,2001,61 ( 15 ):4978-4981.
[16] Raftpoulou M,Etienne-Manneville S,Self A,et al.Regulation of cell migration by the C2 domain of the tumor suppressor PTEN[J].Science,2004,303( 5661):1179-1181.
[17] Fang J,Ding M,Yang L,et al.PI3K/PTEN/AKT signaling regulates prostate tumor angiogenesis[J].Cell Signal,2007,19( 12):2487-2497.
[18] Jiang BH,Liu LZ.PI3K/PTEN signaling in tumorigenesis and angiogenesis[J].Biochim Biophys Acta,2008,1784 ( 1 ):150-158.
[19] Jiang BH,Liu LZ.AKT signaling in regulating angiogenesis[J].Curr Cancer Drug Targets,2008,8( 1):19-26.
[20] Cai J,Ahmad S, Jiang WG, et al.Activation of vascular endothelial growth factor receptor-1 sustains angiogenesis and Bcl-2 expression via the phosphatidylinositol 3-kinase pathway in endothelial cells[J].Diabetes, 2003, 52( 12):2959-2968.
[21] Huang J,Kontos CD.PTEN modulates vascular endothelial growth factor-mediated signaling and angiogenic effect[J].J Biol Chem,2002, 277( 13):10760-10766.
[22] Gimm O,Perren A,Weng LP,et al.Differential nuclear and cytoplasmic expression of PTEN in normal thyroid tissue,and benign and malignant epithelial thyroid tumors[J].Am J Pathol,2000, 156( 5):1693-1700.
[23] Kang YH,Lee HS,Kim WH,et al.Promoter methylation and silencing of PTEN in Gastric carcinoma[J].Lab Invest,2002,82( 3):285-291.
[24] Dahia PLM.PTEN:a unique tumor suppressor gone [J].Endocrine-Related Cancer,2000,7( 2):115-129.
[25] Nos V.Familial non-medullary thyroid carcinoma:an update[J].Endorer Pathol,2008, 19( 4):226-240.
[26] Hou P, Ji M,Xing M.Association of PTEN gene methylation with genetic alterations in the phosphatidylinositol 3-kinase /AKT signaling pathway in thyroid tumors[J].Cancer,2008,113 ( 9):2440-2447.
[27] Jin N,Jiang T,Rosen DM,et al.Dual inhibition of mitogenactivated protein kinase and mammalian target of rapamycin in differentiated and anaplastic thyroid cancer[J].J Clin Endoerinol Metab,2009,94( 10):4107-4112.
[28] Francisco AN,Bussaglia E,Mauricio D,et al.PTEN promoter methylation in sporadic thyroid carcinomas[J].Thyroid,2006,16( 7):633-642.
[29] Bruni P,Boccia A,Baldassarre G,et al.PTEN expression is reduced in a subset of sporadic thyroid carcinomas:evidence that PTEN-growth suppressing activity in thyroid cancer cells mediated by p27kipl [J].Oncogene,2000,19( 28):3146-3155.
[30] Francisco AN,Bussaglia E,Mauricio D,et al.PTEN promoter methylation in sporadic thyroid carcinomas[J].Thyroid,2006,16( 7):633-642.
[31] 殷德涛,尹峰燕,郑立运,等.甲状腺乳头状癌中PTEN 基因启动子甲基化及其蛋白表达的相关性[J].中华耳鼻喉头颈外科杂志,2010,45( 4):330-333.
[32] Steek PA,Pershouse MA,Jasser SA,et al.Identification of a candidate tumor suppressor gene,MMAC1,at chromosome 10q23.3 that is mutated in multiple advanced cancers[J].Nat Genet,1997,15( 4):356-362.

[1]	殷发祥 , 许培权 . 乳腺癌相关基因p16、PTEN、ATM的研究进展. 蚌埠医学院学报, 2016, 41(2): 276-278. doi: 10.13898/j.cnki.issn.1000-2200.2016.02.048
[2]	曲真真 , 石建华 , 汪万英 . nm23和Bcl-2基因在甲状腺肿瘤中的研究进展. 蚌埠医学院学报, 2009, 34(3): 267-269.
[3]	汪运生 , 石建华 , 项平 . 甲状腺乳头状癌中NTRK1基因重排的研究进展. 蚌埠医学院学报, 2011, 36(2): 213-216.
[4]	王春 , 石建华 , 汪万英 . p53和p16基因在甲状腺癌中的研究进展. 蚌埠医学院学报, 2009, 34(5): 455-457.
[5]	王圣应 . 分化型甲状腺癌的外科治疗进展. 蚌埠医学院学报, 2004, 29(6): 571-573.
[6]	刘田 , 张晓梅 . microRNA在甲状腺癌中的研究进展. 蚌埠医学院学报, 2014, 38(3): 417-419.
[7]	林伟 , 石建华 , 项平 , 汪万英 . 甲状腺乳头状癌中BRAF突变的研究进展. 蚌埠医学院学报, 2011, 36(10): 1160-1163.
[8]	李双一 , 石建华 . Caveolin-1在甲状腺癌中的研究进展. 蚌埠医学院学报, 2013, 37(4): 499-502.
[9]	王春 , 石建华 , 汪万英 . p53及p16基因在甲状腺乳头状癌中的表达及意义. 蚌埠医学院学报, 2009, 34(10): 871-873.
[10]	金鑫 , 赵艳 , 喻大军 , 钱军 . 侧方入路在甲状腺肿瘤再次手术中的应用. 蚌埠医学院学报, 2017, 42(6): 720-721,724. doi: 10.13898/j.cnki.issn.1000-2200.2017.06.006
[11]	张晓静 , 祝景伟 , 刘先富 , 陈延松 , 陈晨 , 刘元 , 唐经纬 , 金功圣 . 无充气经腋窝入路腔镜下单侧甲状腺肿瘤切除术的疗效. 蚌埠医学院学报, 2021, 46(11): 1517-1519. doi: 10.13898/j.cnki.issn.1000-2200.2021.11.006
[12]	胡英 , 徐燕 , 韩雪 , 陈高飞 , 陈永侠 . 协同护理指导下积极心理干预联合渐进性肌肉放松训练在甲状腺肿瘤病人围手术期的应用. 蚌埠医学院学报, 2022, 47(9): 1310-1314. doi: 10.13898/j.cnki.issn.1000-2200.2022.09.039
[13]	王浩宇 , 陈兴智 , 王艺雯 . 某大型综合性医院甲状腺肿瘤住院病人流行病学特征分析. 蚌埠医学院学报, 2022, 47(12): 1703-1706. doi: 10.13898/j.cnki.issn.1000-2200.2022.12.019
[14]	高峰 . 食管癌研究现状综述. 蚌埠医学院学报, 2010, 35(6): 645-648.
[15]	叶虹 . 联合运用常规超声、应变弹性成像比值法及声脉冲辐射力成像技术对甲状腺肿块良恶性的诊断意义. 蚌埠医学院学报, 2015, 40(6): 789-791. doi: 10.13898/j.cnki.issn.1000-2200.2015.06.030
[16]	张思铭 , 陈汉 , 杨柳 , 刘梅 . SASH1基因在肿瘤研究中的进展. 蚌埠医学院学报, 2021, 46(5): 699-701. doi: 10.13898/j.cnki.issn.1000-2200.2021.05.035
[17]	蔡兆根 , 于东红 . RASSF1肿瘤抑制基因在人类癌症中的作用. 蚌埠医学院学报, 2007, 32(4): 500-503.
[18]	张磊 , 江浩 . KiSS-1/hOT7T175基因与肿瘤转移的研究进展. 蚌埠医学院学报, 2009, 34(5): 452-454.
[19]	张发良 , 闵大六 . CYP3A基因在肿瘤中的研究进展. 蚌埠医学院学报, 2011, 36(2): 201-204.
[20]	郝海波 , 许培权 . 抑癌基因p16与恶性肿瘤关系的研究进展. 蚌埠医学院学报, 2012, 36(3): 361-363.